• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4602291)   Today's Articles (5045)   Subscriber (49367)
For: Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56. [PMID: 11304787 DOI: 10.1200/jco.2001.19.8.2334] [Citation(s) in RCA: 212] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
Number Cited by Other Article(s)
1
Rakha EA, Tan PH, Quinn C, Provenzano E, Shaaban AM, Deb R, Callagy G, Starczynski J, Lee AHS, Ellis IO, Pinder SE. UK recommendations for HER2 assessment in breast cancer: an update. J Clin Pathol 2023;76:217-227. [PMID: 36564170 DOI: 10.1136/jcp-2022-208632] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Accepted: 12/09/2022] [Indexed: 12/25/2022]
2
Updates on breast biomarkers. Virchows Arch 2022;480:163-176. [PMID: 35029776 DOI: 10.1007/s00428-022-03267-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 12/13/2021] [Accepted: 12/30/2021] [Indexed: 12/22/2022]
3
Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases. Br J Cancer 2021;124:1836-1842. [PMID: 33762723 PMCID: PMC8144199 DOI: 10.1038/s41416-021-01351-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Revised: 02/23/2021] [Accepted: 03/04/2021] [Indexed: 02/01/2023]  Open
4
Hayes DF. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. J Clin Oncol 2021;39:238-248. [DOI: 10.1200/jco.20.01572] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]  Open
5
Shamshirian A, Aref AR, Yip GW, Ebrahimi Warkiani M, Heydari K, Razavi Bazaz S, Hamzehgardeshi Z, Shamshirian D, Moosazadeh M, Alizadeh-Navaei R. Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis. BMC Cancer 2020;20:1049. [PMID: 33129287 PMCID: PMC7603697 DOI: 10.1186/s12885-020-07545-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Accepted: 10/20/2020] [Indexed: 02/08/2023]  Open
6
Song D, Oh YI, Kim JM, Cheon DS, Kim DY, Seo KW. Detection of neurokinin-1 receptor by immunohistochemistry in canine mammary gland tumours. Vet Med Sci 2020;6:958-964. [PMID: 32657032 PMCID: PMC7738737 DOI: 10.1002/vms3.323] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Accepted: 06/11/2020] [Indexed: 12/18/2022]  Open
7
Hayes DF, Rae JM. Pharmacogenomics and Endocrine Therapy in Breast Cancer. J Clin Oncol 2019;38:525-528. [PMID: 31880969 DOI: 10.1200/jco.19.03119] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]  Open
8
Xu B, Shen J, Guo W, Zhao W, Zhuang Y, Wang L. Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer. Pathol Res Pract 2019;215:251-255. [DOI: 10.1016/j.prp.2018.10.035] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Revised: 10/22/2018] [Accepted: 10/31/2018] [Indexed: 10/27/2022]
9
Quaranta M, Daniele A, Coviello M, Savonarola A, Abbate I, Venneri MT, Paradiso A, Stea B, Zito A, Labriola A, Schittulli F. C-Erbb-2 Protein Level in Tissue and Sera of Breast Cancer Patients: A Possibly Useful Clinical Correlation. TUMORI JOURNAL 2018;92:311-7. [PMID: 17036522 DOI: 10.1177/030089160609200409] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
10
Manna EDF, Teixeira LC, Alvarenga M. Association between Immunohistochemical Expression of Topoisomerase IIα, Her2 and Hormone Receptors and Response to Primary Chemotherapy in Breast Cancer. TUMORI JOURNAL 2018. [DOI: 10.1177/030089160609200307] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
11
Dittadi R, Zancan M, Perasole A, Gion M. Evaluation of HER-2/neu in Serum and Tissue of Primary and Metastatic Breast Cancer Patients using an Automated Enzyme Immunoassay. Int J Biol Markers 2018;16:255-61. [PMID: 11820721 DOI: 10.1177/172460080101600406] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
12
Müller V, Thomssen C, Karakas C, Eustermann I, Ramirez Porras J, Coith C, Berger J, Löning T, Jänicke F, Pantel K. Quantitative Assessment of HER-2/Neu Protein Concentration in Breast Cancer by Enzyme-Linked Immunosorbent Assay. Int J Biol Markers 2018;18:13-20. [PMID: 12699058 DOI: 10.1177/172460080301800103] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
13
Biganzoli E, Boracchi P, Marubini E. Biostatistics and Tumor Marker Studies in Breast Cancer: Design, Analysis and Interpretation Issues. Int J Biol Markers 2018;18:40-8. [PMID: 12699062 DOI: 10.1177/172460080301800107] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
14
Loibner M, Oberauner-Wappis L, Viertler C, Groelz D, Zatloukal K. Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation. J Vis Exp 2017. [PMID: 29364207 PMCID: PMC5908343 DOI: 10.3791/55885] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]  Open
15
Morey AL, Brown B, Farshid G, Fox SB, Francis GD, McCue G, von Neumann-Cosel V, Bilous M. Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program. Pathology 2016;48:535-42. [PMID: 27567228 DOI: 10.1016/j.pathol.2016.05.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2016] [Revised: 05/23/2016] [Accepted: 05/29/2016] [Indexed: 10/21/2022]
16
Oberauner-Wappis L, Loibner M, Viertler C, Groelz D, Wyrich R, Zatloukal K. Protocol for HER2 FISH determination on PAXgene-fixed and paraffin-embedded tissue in breast cancer. Int J Exp Pathol 2016;97:202-6. [PMID: 27273709 PMCID: PMC4926048 DOI: 10.1111/iep.12185] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2015] [Accepted: 03/14/2016] [Indexed: 12/24/2022]  Open
17
Tang R, Pennello G. Validation of Prognostic Marker Tests: Statistical Lessons Learned From Regulatory Experience. Ther Innov Regul Sci 2016;50:241-252. [DOI: 10.1177/2168479015601721] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
18
Chin-Yee NJ, Yan AT, Kumachev A, Ko D, Earle C, Tomlinson G, Trudeau ME, Krahn M, Krzyzanowska M, Pal R, Brezden-Masley C, Gavura S, Lien K, Chan K. Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open 2016;4:E66-72. [PMID: 27280116 PMCID: PMC4866921 DOI: 10.9778/cmajo.20150033] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]  Open
19
Suba Z. The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance. DRUG DESIGN DEVELOPMENT AND THERAPY 2015;9:4341-53. [PMID: 26273195 PMCID: PMC4532170 DOI: 10.2147/dddt.s89536] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
20
Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer? Tumour Biol 2015;36:9083-91. [PMID: 26088453 DOI: 10.1007/s13277-015-3661-2] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Accepted: 06/09/2015] [Indexed: 11/27/2022]  Open
21
Jia XQ, Hong Q, Cheng JY, Li JW, Wang YJ, Mo M, Shao ZM, Shen ZZ, Liu GY. Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer. Onco Targets Ther 2015;8:549-55. [PMID: 25767399 PMCID: PMC4354449 DOI: 10.2147/ott.s76879] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]  Open
22
Chu QD, Kim RH. Early Breast Cancers. Surg Oncol 2015. [DOI: 10.1007/978-1-4939-1423-4_4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
23
Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta 2014;440:16-22. [PMID: 25444743 DOI: 10.1016/j.cca.2014.11.001] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2014] [Revised: 11/01/2014] [Accepted: 11/01/2014] [Indexed: 01/17/2023]
24
Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown ME, Aung K, Miller MC, Blossom DL, Schott AF, Henry NL, Rae JM, Connelly MC, Chianese DA, Hayes DF. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res 2014;21:2487-98. [PMID: 25381338 DOI: 10.1158/1078-0432.ccr-14-1913] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2014] [Accepted: 10/13/2014] [Indexed: 02/05/2023]
25
Almeida D, Gerhard R, Leitão D, Davilla C, Damasceno M, Schmitt F. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer. Pathol Res Pract 2014;210:675-9. [PMID: 25042383 DOI: 10.1016/j.prp.2014.06.017] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2013] [Revised: 05/06/2014] [Accepted: 06/24/2014] [Indexed: 11/17/2022]
26
Khandakar B, Mathur SR, Kumar L, Kumar S, Datta Gupta S, Iyer VK, Kalaivani M. Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. BIOMED RESEARCH INTERNATIONAL 2014;2014:401245. [PMID: 24864239 PMCID: PMC4016870 DOI: 10.1155/2014/401245] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Accepted: 03/31/2014] [Indexed: 01/10/2023]
27
Suba Z. Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications. Onco Targets Ther 2014;7:147-64. [PMID: 24482576 PMCID: PMC3905095 DOI: 10.2147/ott.s52600] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]  Open
28
Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Kahlert S, Stieber P. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. Clin Chim Acta 2014;430:86-91. [PMID: 24412321 DOI: 10.1016/j.cca.2013.12.036] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2013] [Revised: 12/13/2013] [Accepted: 12/25/2013] [Indexed: 10/25/2022]
29
Peña L, Gama A, Goldschmidt MH, Abadie J, Benazzi C, Castagnaro M, Díez L, Gärtner F, Hellmén E, Kiupel M, Millán Y, Miller MA, Nguyen F, Poli A, Sarli G, Zappulli V, de las Mulas JM. Canine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry. Vet Pathol 2013;51:127-45. [PMID: 24227007 DOI: 10.1177/0300985813509388] [Citation(s) in RCA: 113] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
30
Chavez-MacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J, Elting L, Smith BD, Hortobagyi GN, Giordano SH. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013;31:4222-8. [PMID: 24127446 DOI: 10.1200/jco.2013.48.7884] [Citation(s) in RCA: 164] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]  Open
31
Lin SH, George TJ, Ben-Josef E, Bradley J, Choe KS, Edelman MJ, Guha C, Krishnan S, Lawrence TS, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman CN, Vikram B, Yoo S, Chung CH. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. J Natl Cancer Inst 2013;105:686-93. [PMID: 23503600 PMCID: PMC3733308 DOI: 10.1093/jnci/djt055] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2012] [Revised: 12/10/2012] [Accepted: 02/20/2013] [Indexed: 01/12/2023]  Open
32
Cheng S, Koch WH, Wu L. Co-development of a companion diagnostic for targeted cancer therapy. N Biotechnol 2012;29:682-8. [DOI: 10.1016/j.nbt.2012.02.002] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2011] [Revised: 02/14/2012] [Accepted: 02/19/2012] [Indexed: 01/25/2023]
33
Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol 2012;25:1098-105. [PMID: 22460807 DOI: 10.1038/modpathol.2012.59] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
34
Yildiz-Aktas IZ, Dabbs DJ, Cooper KL, Chivukula M, McManus K, Bhargava R. The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Am J Clin Pathol 2012;137:691-8. [PMID: 22523206 DOI: 10.1309/ajcpqrag67gjrpmt] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]  Open
35
Yang YL, Fan Y, Lang RG, Gu F, Ren MJ, Zhang XM, Yin D, Fu L. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance. Breast Cancer Res Treat 2012;134:1095-102. [DOI: 10.1007/s10549-012-2046-0] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2012] [Accepted: 03/20/2012] [Indexed: 11/30/2022]
36
Taube SE, Lively T. Challenges in drug and biomarker co-development. Recent Results Cancer Res 2012;195:229-239. [PMID: 22527510 DOI: 10.1007/978-3-642-28160-0_21] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
37
Melichar B, Plebani M. Targeted therapy for HER-2: personalized medicine for her, too. Clin Chem Lab Med 2012;50:1-4. [DOI: 10.1515/cclm.2011.724] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
38
Distinguishing breast cancer cells using surface-enhanced Raman scattering. Anal Bioanal Chem 2011;402:1093-100. [PMID: 22124755 DOI: 10.1007/s00216-011-5577-z] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2011] [Revised: 11/11/2011] [Accepted: 11/11/2011] [Indexed: 10/15/2022]
39
HER2 gene amplification in patients with breast cancer with equivocal IHC results. J Clin Pathol 2011;64:1069-72. [DOI: 10.1136/jclinpath-2011-200019] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
40
Park S, Park HS, Koo JS, Yang WI, Kim SI, Park BW. Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization. Cancer 2011;118:914-23. [PMID: 21800290 DOI: 10.1002/cncr.26406] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2010] [Revised: 03/16/2011] [Accepted: 06/08/2011] [Indexed: 02/01/2023]
41
Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer 2011;19:309-14. [PMID: 21725655 DOI: 10.1007/s12282-011-0291-4] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2011] [Accepted: 06/14/2011] [Indexed: 10/18/2022]
42
Goddard KAB, Weinmann S, Richert-Boe K, Chen C, Bulkley J, Wax C. HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics 2011;15:1-10. [PMID: 21540562 DOI: 10.1159/000325746] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2010] [Accepted: 02/16/2011] [Indexed: 01/06/2023]  Open
43
Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol 2011;22:2387-2393. [PMID: 21406473 DOI: 10.1093/annonc/mdq786] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
44
Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis. Med Oncol 2011;29:459-65. [PMID: 21359639 DOI: 10.1007/s12032-011-9869-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2011] [Accepted: 02/13/2011] [Indexed: 10/18/2022]
45
González-Reyes S, Fernández JM, González LO, Aguirre A, Suárez A, González JM, Escaff S, Vizoso FJ. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 2011;60:217-26. [PMID: 20978888 PMCID: PMC11028925 DOI: 10.1007/s00262-010-0931-0] [Citation(s) in RCA: 99] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2010] [Accepted: 10/07/2010] [Indexed: 12/12/2022]
46
Melichar B, Plebani M. Laboratory medicine: an essential partner in the care of cancer patients. Clin Chem Lab Med 2011;49. [DOI: 10.1515/cclm.2011.244] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
47
Hayes D, Paoletti C. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/j.breastdis.2011.03.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
48
Mazouni C, Fina F, Romain S, Ouafik L, Bonnier P, Brandone JM, Martin PM. Epstein-Barr virus as a marker of biological aggressiveness in breast cancer. Br J Cancer 2010;104:332-7. [PMID: 21179039 PMCID: PMC3031896 DOI: 10.1038/sj.bjc.6606048] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]  Open
49
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer 2010;103:1335-42. [PMID: 20978512 PMCID: PMC2990615 DOI: 10.1038/sj.bjc.6605939] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]  Open
50
Roy R, Coticchia CM, Yang J, Moses MA. Biomarkers in Cancer. Biomarkers 2010. [DOI: 10.1002/9780470918562.ch14] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
PrevPage 1 of 4 1234Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA